Table 1 Patient characteristics at the time of diagnosis.

From: Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies

Variables

N = 21

Age, y

Median (Range)

34 (17–54)

 < 35/ ≥ 35

12 (57.1%)/9 (42.9%)

Sex

Female/Male

7 (33.3%)/14 (66.7%)

PS

0–1/2–4

13 (61.9%)/8 (38.1%)

Ann Arbor stage

I-II/III-IV

3 (14.3%)/18 (85.7%)

IPI

0–2/3–5/NA

10 (47.6%)/10 (47.6%)/1 (4.8%)

BM involvement

Y (blast%; median, range)

9 (42.9%), 3.2% (1.8%-18.5%)

Extranodal lesions

Mediastinum/Pleura/Pericardium

13 (61.9%)/11 (52.4%)

Lung/Liver/GI tract

3 (14.3%)/2 (9.5%)/2 (9.5%)

CNS

0 (0.0%)

LDH

 ≤ / > ULN/NA

12 (57.1%)/8 (38.1%)/1 (4.8%)

  1. PS performance status, IPI international prognostic index, NA not available, BM bone marrow, GI gastrointestinal, CNS central nervous system, LDH lactate dehydrogenase, ULN upper limit of normal.
Back to article page